On September 9, 2023, Biosyngen Pte Ltd (hereinafter referred to as "Biosyngen") announced that the United States FDA has approved the Phase I/II investigational New drug (IND) to apply for the third first-line therapy BRL03 for the treatment of advanced solid tumors such as lung cancer and stomach cancer.

Notably, BRL03 is also the first TCR-T product developed by Bagel Bioto to enter clinical trials. This significant achievement is due to the company's cutting-edge technology and the extensive accumulation of capabilities and resources over the years.

BRL03 is a T-cell receptor (TCR) therapy that isolates a patient's T cells and then genetically modifies them to target specific cell antigens. These modified T cells are then injected back into the patient.